#	Pagina
attuale pagina	/open-h2020/projects/209461/index.html
-1	/open-consip/fornitori/2020/profilo-01156710624/index.html
-2	/open-h2020/projects/198060/index.html
-3	/open-consip/fornitori/2020/profilo-01476460629/index.html
-4	/open-h2020/projects/210669/index.html
-5	/open-consip/fornitori/2020/profilo-08151321000/index.html
-6	/open-consip/fornitori/2020/profilo-06759291211/index.html
-7	/open-h2020/per-coordinator/is/jakar+ehf/index.html
-8	/open-h2020/projects/211444/index.html
-9	/open-consip/fornitori/2020/profilo-02135280796/index.html
-10	/open-consip/fornitori/2020/profilo-01471661213/index.html

Opendata, web and dolomites

ADAPTED SIGNED

Alzheimers Disease Apolipoprotein Pathology for Treatment Elucidation and Development - Sofia ref.: 115975

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Outcomes and
results

ADAPTED project word cloud

Explore the words cloud of the ADAPTED project. It provides you a very rough idea of what is the project "ADAPTED" about.

diagnostics utility ad 4 proof cohorts backbone phenotype leverage uncover capacity genotypes longitudinal culture extreme human pleiotropic modulation validation astrocyte gene co biomarkers attenuate omics earliest endocytosis free back rising biology endothelium differentiate models vision macrophage cohort quantitative proposes focussed largely cells seminal hypothesis unknown immune signalling vasculature risk temporal predictive homeostasis lines identification marker effort tide 3 suffering treatment metabolism brain chip load fundamental rigorous generate 25 homozygote illuminate embark stages form blood mci neuron dating dimension series stem organ assays mechanisms bespoke clinical progression combination apoe proteomics editing create combined ipsc pluripotent performed signatures 2 acts influence experiments validating lipid demands complexity data consistency broad follow diagnostic harmonised therapies biological

Project "ADAPTED" data sheet

The following table provides information about the project.

Coordinator	FUNDACIO ACE Organization address address: MARQUES DE SENTMENAT 57 city: BARCELONA postcode: 8014 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Spain [ES]
Project website	https://imi-adapted.eu
Total cost	6˙796˙740 €
EC max contribution	3˙510˙000 € (52%)
Programme	1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
Code Call	H2020-JTI-IMI2-2015-05-two-stage
Funding Scheme	IMI2-RIA
Starting year	2016
Duration (year-month-day)	from 2016-10-01 to 2020-03-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	FUNDACIO ACE FUNDACIO ACE Organization address address: MARQUES DE SENTMENAT 57 city: BARCELONA postcode: 8014 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (BARCELONA)	coordinator	333˙757.00
2	AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS Organization address address: CALLE SERRANO 117 city: MADRID postcode: 28006 website: http://www.csic.es contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (MADRID)	participant	688˙476.00
3	UNIVERSITEIT LEIDEN UNIVERSITEIT LEIDEN Organization address address: RAPENBURG 70 city: LEIDEN postcode: 2311 EZ website: www.universiteitleiden.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (LEIDEN)	participant	470˙677.00
4	UNIVERSITATSKLINIKUM BONN UNIVERSITATSKLINIKUM BONN Organization address address: VENUSBERG-CAMPUS 1 city: BONN postcode: 53127 website: www.ukb.uni-bonn.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (BONN)	participant	429˙850.00
5	ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM Organization address address: DR MOLEWATERPLEIN 40 city: ROTTERDAM postcode: 3015 GD website: www.erasmusmc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (ROTTERDAM)	participant	420˙500.00
6	MIMETAS BV MIMETAS BV Organization address address: JH Oortweg 19 city: Leiden postcode: 2333CH website: www.mimetas.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (Leiden)	participant	305˙102.00
7	CAEBI BIOINFORMATICA SOCIEDAD LIMITADA CAEBI BIOINFORMATICA SOCIEDAD LIMITADA Organization address address: RIO DE LA PLATA 2 BAJO 4 city: SEVILLA postcode: 41013 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (SEVILLA)	participant	282˙062.00
8	KLINIKUM DER UNIVERSITAET ZU KOELN KLINIKUM DER UNIVERSITAET ZU KOELN Organization address address: Kerpener Strasse 62 city: KOELN postcode: 50937 website: www.uk-koeln.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (KOELN)	participant	244˙812.00
9	DC BIOSCEINCES LTD DC BIOSCEINCES LTD Organization address address: JAMES LINDSAY PLACE 3 DUNDEE TECHNOPOLE city: DUNDEE postcode: DD1 5JJ website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (DUNDEE)	participant	186˙514.00
10	MODUS RESEARCH AND INNOVATION LIMITED MODUS RESEARCH AND INNOVATION LIMITED Organization address address: 7-11 MELVILLE STREET city: EDINBURGH postcode: EH3 7PE website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (EDINBURGH)	participant	110˙337.00
11	KITE INNOVATION (EUROPE) LIMITED KITE INNOVATION (EUROPE) LIMITED Organization address address: 3M BUCKLEY INNOVATION CENTRE city: HUDDERSFIELD postcode: HD1 3BD website: www.kiteinnovation.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (HUDDERSFIELD)	participant	37˙912.00
12	ABBVIE DEUTSCHLAND GMBH & CO KG ABBVIE DEUTSCHLAND GMBH & CO KG Organization address address: MAINZER STR. 81 city: WIESBADEN postcode: 65205 website: http://www.abbvie.de/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (WIESBADEN)	participant	0.00
13	BIOGEN IDEC LIMITED BIOGEN IDEC LIMITED Organization address address: INNOVATION HOUSE 70 NORDEN ROAD city: MAIDENHEAD postcode: SL6 3AY website: http://www.biogen.com/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (MAIDENHEAD)	participant	0.00
14	JANSSEN PHARMACEUTICA NV JANSSEN PHARMACEUTICA NV Organization address address: TURNHOUTSEWEG 30 city: BEERSE postcode: 2340 website: www.janssenpharmaceutica.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (BEERSE)	participant	0.00

Map

Project objective

APOEÉ›4 has long been known as a risk factor of LOAD, yet the biological mechanisms through which it acts remain largely unknown and affect both the vasculature and the brain. This complexity and pleiotropic influence demands an integrated hypothesis-free approach to embark on a fundamental study of the gene, the phenotype and modulation by other risk factors. ADAPTED proposes to leverage extreme genotypes from consortium cohorts dating back more than 25 years to generate, and use existing, lines of human induced pluripotent stem cells (iPSC). These cells, with blood cells, will form the backbone of the research programme. We will differentiate them to the most relevant cells for APOE and AD studies and with gene editing create bespoke homozygote É›3 and É›2 cells for a highly focussed effort on APOE biology. A series of experiments including neuron-astrocyte and macrophage-endothelium co-culture and Organ on a Chip models combined with state-of-the-art omics including quantitative proteomics assays will generate data for rigorous integrated analysis to uncover new signalling pathways related to APOE. Lipid homeostasis, endocytosis, metabolism and immune systems pathways will be investigated in a broad approach. The findings are expected to lead to identification of new treatment approaches and blood based AD signatures with a temporal dimension from the earliest stages of risk identification and progression through MCI to AD. Testing and validation of biomarkers will be performed by examining their influence and predictive capacity in a longitudinal ADAPTED cohort harmonised using a combination of approaches for marker and diagnostic consistency. The impact of this work can be expected to include seminal new finding to illuminate the research path towards new diagnostics and therapies to attenuate the rising tide of suffering from AD. The vision is a follow on with clinical proof of concept validating utility of the results within two years of the end of ADAPTED.

Deliverables

List of deliverables.
Definition of cognitive composite scores to evaluate rate of disease progression based on cognitive function decline in the ADAPTED cohorts	Websites, patent fillings, videos etc.	2020-04-08 21:10:07

Take a look to the deliverables list in detail: detailed list of ADAPTED deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2018	Michael Peitz, Tamara Bechler, Catrin Cornelia Thiele, Monika Veltel, Melanie Bloschies, Klaus Fliessbach, Alfredo Ramirez, Oliver BrÃ¼stle Blood-derived integration-free iPS cell line UKBi011-A from a diagnosed male Alzheimer\'s disease patient with APOE É›4/É›4 genotype published pages: 250-253, ISSN: 1873-5061, DOI: 10.1016/j.scr.2018.04.011	Stem Cell Research 29	2020-04-08
2018	Sven J. van der Lee, Charlotte E. Teunissen, RenÃ© Pool, Martin J. Shipley, Alexander Teumer, Vincent Chouraki, Debora Melo van Lent, Juho Tynkkynen, Krista Fischer, Jussi Hernesniemi, Toomas Haller, Archana Singh-Manoux, Aswin Verhoeven, Gonneke Willemsen, Francisca A. de Leeuw, Holger Wagner, Jenny van Dongen, Johannes Hertel, Kathrin Budde, Ko Willems van Dijk, Leonie Weinhold, M. Arfan Ikram, Maik Pietzner, Markus Perola, Michael Wagner, Nele Friedrich, P. Eline Slagboom, Philip Scheltens, Qiong Yang, Robert E. Gertzen, Sarah Egert, Shuo Li, Thomas Hankemeier, Catharina E.M. van Beijsterveldt, Ramachandran S. Vasan, Wolfgang Maier, Carel F.W. Peeters, Hans JÃ¶rgen Grabe, Alfredo Ramirez, Sudha Seshadri, Andres Metspalu, Mika KivimÃ¤ki, Veikko Salomaa, AyÅŸe Demirkan, Dorret I. Boomsma, Wiesje M. van der Flier, Najaf Amin, Cornelia M. van Duijn Circulating metabolites and general cognitive ability and dementia: Evidence from 11 cohort studies published pages: , ISSN: 1552-5260, DOI: 10.1016/j.jalz.2017.11.012	Alzheimer\'s & Dementia	2020-04-08
2018	Nienke R. Wevers, Dhanesh G. Kasi, Taylor Gray, Karlijn J. Wilschut, Benjamin Smith, Remko van Vught, Fumitaka Shimizu, Yasuteru Sano, Takashi Kanda, Graham Marsh, Sebastiaan J. Trietsch, Paul Vulto, HenriÃ«tte L. Lanz, Birgit Obermeier A perfused human bloodâ€“brain barrier on-a-chip for high-throughput assessment of barrier function and antibody transport published pages: , ISSN: 2045-8118, DOI: 10.1186/s12987-018-0108-3	Fluids and Barriers of the CNS 15/1	2020-04-08

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ADAPTED" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ADAPTED" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More

PD-MIND (2019)

Parkinson Disease with Mild cognition Impairment treated with Nicotinic agonist Drug

Read More

GNA NOW (2019)

NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

Read More